- Home
- AEG vs MRNA Comparison
AEG vs MRNA Comparison
Compare AEG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEG | MRNA |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 9.3B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | AEG | MRNA |
|---|---|---|
| Price | $7.82 | $27.57 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $33.91 |
| AVG Volume (30 Days) | 5.5M | ★ 9.9M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $15,344,685,849.00 | $2,232,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.04 | $0.77 |
| P/E Ratio | $8.28 | ★ N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $5.42 | $22.28 |
| 52 Week High | $8.15 | $48.92 |
Technical Indicators
Market Signals| Indicator | AEG | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 60.85 |
| Support Level | $7.81 | $23.92 |
| Resistance Level | $7.99 | $26.00 |
| Average True Range (ATR) | 0.10 | 1.29 |
| MACD | 0.02 | 0.32 |
| Stochastic Oscillator | 65.83 | 99.82 |
Price Performance
Historical ComparisonAbout AEG Aegon Ltd. New York Registry Shares
Aegon is a life insurance and long-term savings business listed in the Netherlands. It listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. Over recent years, Aegon has been moving through an extensive transformation program where management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the group that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile-earnings products and recycle funds into capital-light and more predictable strategic businesses.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.